Overview

* Nuvation Bio ( NUVB ) beat analysts' expectations for Q3 revenue, driven by IBTROZI sales

* Company reported Q3 net loss of $55.8 mln

* 204 patients started on IBTROZI in Q3, indicating strong launch progress

Outlook

* Company expects $25 mln milestone payment from Nippon Kayaku by year-end

* Nuvation Bio ( NUVB ) plans sNDA to update IBTROZI label with recent data

* Company expects taletrectinib listing on China's National Reimbursement Drug List in 2026

Result Drivers

* IBTROZI LAUNCH - 204 patients started treatment with IBTROZI in Q3, reflecting strong launch progress

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $13.12 $6.61

Revenue mln mln (7

Analysts

)

Q3 EPS -$0.16

Q3 Net -$55.79

Income mln

Q3 -$56.43

Income mln

from

Pperatio

ns

Q3 $66.20

Operatin mln

g

Expenses

Q3 -$55.79

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nuvation Bio Inc ( NUVB ) is $10.00, about 47.8% above its October 31 closing price of $5.22

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)